0.222.2392979/7050-7051 muzaffermetintas@gmail.com +0.222.2394714

Mesleki Tam Metin Bazı Makaleler

Ayrıntılar
Gösterim: 12337

Turkish Mesothelioma Surveiallance and Environmental Asbestos Control Program

The Safety of Medical Thoracoscopy in a Group at High Risk for Complications

Environmental asbestos exposure in rural Turkey and risk of lung cancer

Relationship of tumor size and malignant meothelioma tumor response to chemotherapy

Cisplatin, mitomycin, and interferon-alpha 2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma

Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.

Computed tomography  features in malignant pleural mesothelioma and other commonly seen pleural diseases

Detecting extrathoracic metastases in patients with non-small cell lung cancer: Is routine scanning necessary?

Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors.

Environmental asbestos exposure and malignant pleural mesothelioma.

Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure.

Increased pleural fluid adenosıne deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.

Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.

Outcome of patients diagnosed with fibrinous pleuritis after medical thoracoscopy.

Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.

Trimodality Treatment of Malignant Pleural Mesothelioma

A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005. A single institution experience.

Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.

Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.

Predictors of talc pleurodesis outcome in patients with malignant pleural effusions.

Lung cancer in individuals less than 50 years of age.

Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma

Malignant mesothelioma due to environmental exposure to asbestos.

Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort.

Vascular endothelial growth factor levels in active pulmonary tuberculosis

Non-malignant pleural lesions due to environmental exposure to asbestos

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features
and prognosis of mesotheliomas with environmental asbestos exposure

Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.

MicroRNA and mRNA features of malignant plural mesotehlioma and benign asbestos-related effusion

Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies

Determination of the Relationship Between rs4986790 and rs4986791 Variants of TLR4 Gene and Lung Cancer

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma

Adoption of pleurectomy and decortication for malignant mesothelioma  leads to similar survival as extrapleural pleurectomy

CT-scan guided Abrams needle pleural biopsy versus ultrasound assisted cutting needle pleural biopsy for diagnosis in patients with malignant pleural mesothelioma



Eskişehir Osmangazi Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Eskişehir.

  • 0.222.2392979/7050-7051
  • muzaffermetintas@gmail.com
  • 0.222.2394714

Hızlı Linkler

Tavsiye Linkler